Drug Trial Radar · NCT03201770
Cohort Event Monitoring Study of Pyramax®
Last checked: Nov 19, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,572
Actual
Start
Jun 22, 2017
Primary completion
Apr 10, 2019
Study completion Apr 10, 2019
Sponsor
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Medicines for Malaria Venture
- First posted
- Jun 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes. The study is to assess the safety of Pyramax, particularly in patients with underlying liver function abnormalities, in patients who have co-morbid conditions, such as HIV, and also in very small children (\<1 year of age).
Conditions
- Malaria,Falciparum
Interventions
pyronaridine artesunateDrug
Antimalarial treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation and identification of hepatic safety events, including raised liver function testsTime frame: Assessment up to Day 28.
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
The Biotechnology Center Nkolbisson, Univ of Yaounde I, Messa
Yaoundé, Cameroon
Institut Pierre Richet / Institut National de SanPublique (IPR/INSP)
Bouaké, Côte d’Ivoire
Centre de Recherche du Centre Hospitalier du Mont Amba
Kinshasa, Democratic Republic of the Congo
CERMEL, Albert Schweitzer Hospital
Lambaréné, Gabon
Centre de Santé FCRM, Hospital of Talangai
Brazzaville, Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.